Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nam H Dang

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|March 23, 2004
CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapyUgur Aytac, Nam H Dang
International Journal of Oncology|February 13, 2003
CD26: a novel treatment target for T-cell lymphoid malignancies? (Review)Kazuya Sato, Nam H Dang
Expert Opinion on Biological Therapy|December 26, 2012
The role of monoclonal antibodies in the treatment of lymphomasJack W Hsu, Nam H Dang
Clinical Journal of Oncology Nursing|April 28, 2004
Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphomaPamela L Walker, Nam H Dang
Clinical Lymphoma & Myeloma|December 17, 2008
Novel antibody approaches for T-cell lymphomasOscar B Goodman, Nam H Dang
Trends in Immunology|May 6, 2008
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell functionKei Ohnuma, Nam H Dang, Chikao Morimoto
Modern Rheumatology|October 5, 2018
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapyKei Ohnuma, Ryo Hatano, Nam H Dang, et al.
Case Reports in Surgery|March 12, 2020
Successful Surgical Removal of the Largest Known SpleenDavid J Hall, Nam H Dang, Christiana M Shaw
Cureus|May 26, 2021
Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous SystemsAnthony D Sorrentino, Amar H Kelkar, Nam H Dang
Clinical Journal of Oncology Nursing|October 10, 2008
Bendamustine: a novel cytotoxic agent for hematologic malignanciesSusan Blumel, Amy Goodrich, Cheryl Martin, et al.
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|March 23, 2004
CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapyUgur Aytac, Nam H Dang
International Journal of Oncology|February 13, 2003
CD26: a novel treatment target for T-cell lymphoid malignancies? (Review)Kazuya Sato, Nam H Dang
Expert Opinion on Biological Therapy|December 26, 2012
The role of monoclonal antibodies in the treatment of lymphomasJack W Hsu, Nam H Dang
Clinical Journal of Oncology Nursing|April 28, 2004
Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphomaPamela L Walker, Nam H Dang
Clinical Lymphoma & Myeloma|December 17, 2008
Novel antibody approaches for T-cell lymphomasOscar B Goodman, Nam H Dang
Trends in Immunology|May 6, 2008
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell functionKei Ohnuma, Nam H Dang, Chikao Morimoto
Modern Rheumatology|October 5, 2018
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapyKei Ohnuma, Ryo Hatano, Nam H Dang, et al.
Case Reports in Surgery|March 12, 2020
Successful Surgical Removal of the Largest Known SpleenDavid J Hall, Nam H Dang, Christiana M Shaw
Cureus|May 26, 2021
Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous SystemsAnthony D Sorrentino, Amar H Kelkar, Nam H Dang
Clinical Journal of Oncology Nursing|October 10, 2008
Bendamustine: a novel cytotoxic agent for hematologic malignanciesSusan Blumel, Amy Goodrich, Cheryl Martin, et al.
Pageof 13